A carregar...
Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moderate to severe Crohn’s disease (CD) in children. Like infliximab, the first biologic agent used to treat pediatric CD, regulatory app...
Na minha lista:
| Publicado no: | Pediatric Health Med Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683269/ https://ncbi.nlm.nih.gov/pubmed/29388607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S40948 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|